Ngā hua rapu - Ravi Salgia

Whakamahine hua
  1. 1
    Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer

    Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer mā Ravi Salgia

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    MET Pathway as a Therapeutic Target

    MET Pathway as a Therapeutic Target mā Eric S. Kim, Ravi Salgia

    I whakaputaina 2009
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer

    Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer mā Neelu Puri, Ravi Salgia

    I whakaputaina 2008
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer

    The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer mā Ravi Salgia, Prakash Kulkarni

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Managing Patients With Relapsed Small-Cell Lung Cancer

    Managing Patients With Relapsed Small-Cell Lung Cancer mā Jun Gong, Ravi Salgia

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer

    The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer mā Martin Sattler, Ravi Salgia

    I whakaputaina 2025
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    MET molecular mechanisms and therapies in lung cancer

    MET molecular mechanisms and therapies in lung cancer mā Ryan E. Lawrence, Ravi Salgia

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    MET As a Possible Target for Non–Small-Cell Lung Cancer

    MET As a Possible Target for Non–Small-Cell Lung Cancer mā Ahad A. Sadiq, Ravi Salgia

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    The role of chemokine receptor CXCR4 in lung cancer

    The role of chemokine receptor CXCR4 in lung cancer mā Tara C. Gangadhar, Suvobroto Nandi, Ravi Salgia

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Chemokine Receptors CXCR-1/2 Activate Mitogen-activated Protein Kinase via the Epidermal Growth Factor Receptor in Ovarian Cancer Cells

    Chemokine Receptors CXCR-1/2 Activate Mitogen-activated Protein Kinase via the Epidermal Growth Factor Receptor in Ovarian Cancer Cells mā Gita Venkatakrishnan, Ravi Salgia, Jerome E. Groopman

    I whakaputaina 2000
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer

    The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer mā Mandira Ray, Ravi Salgia, Everett E. Vokes

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Tumor Heterogeneity and Therapeutic Resistance

    Tumor Heterogeneity and Therapeutic Resistance mā Christine M. Lovly, April K.S. Salama, Ravi Salgia

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin

    A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin mā C. Patrick, Erik Schaefer, James G. Christensen, Ravi Salgia

    I whakaputaina 2005
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Role of MetMAb (OA-5D5) in c-MET active lung malignancies

    Role of MetMAb (OA-5D5) in c-MET active lung malignancies mā Mosmi Surati, Premal H. Patel, Amy Peterson, Ravi Salgia

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

    Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations mā Jun Gong, Alex Chehrazi‐Raffle, Srikanth Reddi, Ravi Salgia

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    The Mitochondrion as an Emerging Therapeutic Target in Cancer

    The Mitochondrion as an Emerging Therapeutic Target in Cancer mā Katherine G. Roth, Isa Mambetsariev, Prakash Kulkarni, Ravi Salgia

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    FAK and paxillin, two potential targets in pancreatic cancer

    FAK and paxillin, two potential targets in pancreatic cancer mā Rajani Kanteti, Surinder K. Batra, Frances E. Lennon, Ravi Salgia

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience

    Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience mā Jun Gong, May Cho, Marvin Sy, Ravi Salgia, Marwan Fakih

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping

    The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mā Ravi Salgia, Martin Sattler, Juergen Scheele, Christopher Stroh, Enriqueta Felip

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

    The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) mā Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, Arin Nam, Martin Sattler

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: